"Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing in the diagnosis and treatment of cancer and blood disorders. With locations spanning the southeast region of Virginia and Northeastern North Carolina, we are able to extend services and treatments to patients, including medical oncology, radiation oncology, gynecologic oncology, hematology, diagnostics, clinical research, stem cell transplantation, genetic counseling, and psychosocial oncology."

During the past decade, Virginia Oncology Associates-Hampton conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 31 clinical trials were completed, i.e. on average, 221.4% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 14 clinical trials were completed. i.e. 700% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia Oncology Associates-Hampton" #1 sponsor was "National Cancer Institute (NCI)" with 13 trials, followed by "Alliance for Clinical Trials in Oncology" with 9 trials sponsored, "Pfizer" with 7 trials sponsored, "NSABP Foundation Inc" with 6 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 6 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia Oncology Associates-Hampton" #1 collaborator was "National Cancer Institute (NCI)" with 20 trials as a collaborator, "SWOG Cancer Research Network" with 7 trials as a collaborator, "NCIC Clinical Trials Group" with 5 trials as a collaborator, "North Central Cancer Treatment Group" with 5 trials as a collaborator and "Cancer and Leukemia Group B" with 4 trials as a collaborator. Other collaborators include 26 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Virginia Oncology Associates-Hampton" are "Breast Cancer" (7 trials), "Prostate Cancer" (7 trials), "Colorectal Cancer" (6 trials), "Lung Cancer" (3 trials) and "Stage IIA Breast Cancer AJCC v6 and v7" (3 trials). Many other conditions were trialed in "Virginia Oncology Associates-Hampton" in a lesser frequency.

Most popular intervention types in "Virginia Oncology Associates-Hampton" are "Drug" (48 trials), "Other" (17 trials), "Biological" (14 trials), "Radiation" (6 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (13 trials), "Paclitaxel" (10 trials), "Bevacizumab" (9 trials), "Carboplatin" (7 trials) and "Placebo" (7 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Oncology Associates-Hampton" are 32 trials for "All" genders, 13 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are NaN active trials in "Virginia Oncology Associates-Hampton". undefined are not yet recruiting, 2 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Virginia Oncology Associates-Hampton, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Oncology Associates-Hampton, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".